Tasman Armytage

Gosford, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Underweight BMI Independently Predicts Inferior Survival in DLBCL Treated With R-CHOP: A Lymphoma Registry Study.

Underweight BMI Independently Predicts Inferior Survival in DLBCL Treated With R-CHOP: A Lymphoma Registry Study.

Journal: European journal of haematology

Published: April 14, 2026

Real-World Retrospective Analysis of Daratumumab for Relapsed or Refractory Multiple Myeloma in Regional Australia.

Real-World Retrospective Analysis of Daratumumab for Relapsed or Refractory Multiple Myeloma in Regional Australia.

Journal: Asia-Pacific journal of clinical oncology

Published: March 15, 2026

Blinatumomab in de novo AYA ALL-Results of the Australasian Leukaemia and Lymphoma Group ALL09 "SUBLIME" study.

Blinatumomab in de novo AYA ALL-Results of the Australasian Leukaemia and Lymphoma Group ALL09 "SUBLIME" study.

Journal: HemaSphere

Published: July 23, 2025

Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.

Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 17, 2025

ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL.

ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL.

Journal: Blood advances

Published: November 18, 2024

Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry.

Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry.

Journal: Leukemia & lymphoma

Published: February 20, 2024

Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project.

Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project.

Journal: EJHaem

Published: November 28, 2023

Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies.

Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies.

Journal: Internal medicine journal

Published: May 24, 2022

Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.

Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.

Journal: Internal medicine journal

Published: May 07, 2021

COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement.

COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement.

Journal: Internal medicine journal

Published: February 01, 2021

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic.

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic.

Journal: Internal medicine journal

Published: April 08, 2020

Intensive chemotherapy and up-front stem cell transplant for double hit lymphoma.

Intensive chemotherapy and up-front stem cell transplant for double hit lymphoma.

Journal: Bone marrow transplantation

Published: December 18, 2019

Showing 1-12 of 15

Last Updated: 09/26/2026